REGNT1

REGENERON PHARMACEUTICALS, INC.

Financial Intelligence

Scored 8/30/2026

Buffett Quality

2.0/10

Lynch Category

Stalwart

Margin of Safety

Acquisition Risk

Not flagged

Owner Earnings

$5.0B

Recent Signals

20 found
earnings_call_nlp

REGENERON PHARMACEUTICALS, INC.

news_score: null · bearish_pct: null · bullish_pct: null

7/30/2026

30%

financial_quality

REGENERON PHARMACEUTICALS, INC.

source: edgar_efts · fund_count: 2 · fund_names: Invesco Ltd.

7/15/2026

65%

insider_transaction

REGENERON PHARMACEUTICALS, INC.

is_buy: false · shares: 200 · filing_date: 2026-07-07

7/7/2026

50%

insider_transaction

REGENERON PHARMACEUTICALS, INC.

is_buy: false · shares: 24 · filing_date: 2026-05-04

5/4/2026

50%

Talent

REGENERON PHARMACEUTICALS, INC.

role: Executive · event_type: appointment · interpretation: C-suite appointment — monitor for subsequent strategic announcements

7/23/2024

45%

Talent

REGENERON PHARMACEUTICALS, INC.

role: Executive · event_type: appointment · interpretation: C-suite appointment — monitor for subsequent strategic announcements

7/23/2024

45%

Talent

REGENERON PHARMACEUTICALS, INC.

role: Executive · event_type: appointment · interpretation: C-suite appointment — monitor for subsequent strategic announcements

7/23/2024

45%

Talent

REGENERON PHARMACEUTICALS, INC.

role: Executive · event_type: appointment · interpretation: C-suite appointment — monitor for subsequent strategic announcements

7/23/2024

45%

Talent

REGENERON PHARMACEUTICALS, INC.

role: Executive · event_type: appointment · interpretation: C-suite appointment — monitor for subsequent strategic announcements

7/23/2024

45%

Talent

REGENERON PHARMACEUTICALS, INC.

role: Executive · event_type: appointment · interpretation: C-suite appointment — monitor for subsequent strategic announcements

1/31/2024

45%

Talent

REGENERON PHARMACEUTICALS, INC.

role: Executive · event_type: appointment · interpretation: C-suite appointment — monitor for subsequent strategic announcements

1/31/2024

45%

Talent

REGENERON PHARMACEUTICALS, INC.

role: Executive · event_type: appointment · interpretation: C-suite appointment — monitor for subsequent strategic announcements

1/31/2024

45%

Talent

REGENERON PHARMACEUTICALS, INC.

role: Executive · event_type: appointment · interpretation: C-suite appointment — monitor for subsequent strategic announcements

1/31/2024

45%

Talent

REGENERON PHARMACEUTICALS, INC.

role: Executive · event_type: appointment · interpretation: C-suite appointment — monitor for subsequent strategic announcements

1/31/2024

45%

Talent

REGENERON PHARMACEUTICALS, INC.

role: Executive · event_type: appointment · interpretation: C-suite appointment — monitor for subsequent strategic announcements

9/8/2023

45%

Talent

REGENERON PHARMACEUTICALS, INC.

role: Executive · event_type: appointment · interpretation: C-suite appointment — monitor for subsequent strategic announcements

9/8/2023

45%

Talent

REGENERON PHARMACEUTICALS, INC.

role: Executive · event_type: appointment · interpretation: C-suite appointment — monitor for subsequent strategic announcements

9/8/2023

45%

Talent

REGENERON PHARMACEUTICALS, INC.

role: Executive · event_type: appointment · interpretation: C-suite appointment — monitor for subsequent strategic announcements

9/8/2023

45%

Talent

REGENERON PHARMACEUTICALS, INC.

role: Executive · event_type: appointment · interpretation: C-suite appointment — monitor for subsequent strategic announcements

9/8/2023

45%

Talent

REGENERON PHARMACEUTICALS, INC.

role: Executive · event_type: appointment · interpretation: C-suite appointment — monitor for subsequent strategic announcements

7/12/2023

45%

Watch Reason

S&P 500 / major index component — seeded via EDGAR